SEATTLE and SAN FRANCISCO – (October 3, 2017) –Arzeda Corp, “The Protein Design Company™,” and TeselaGen Biotechnology Inc., a software company providing automated DNA design solutions with it’s Synthetic Evolution™ software platform, today announced that Arzeda will license TeselaGen’s proprietary cloud-based informatics solution and collaborate to extend TeselaGen’s state-of-the-art biological design automation platform.
“TeselaGen’s industry-leading software tools complement our own technology stack. With the deployment of TeselaGen’s software tools at Arzeda, we will improve our protein design pipeline throughput and implement our computationally designed enzymes and metabolic pathways more efficiently” stated Alexandre Zanghellini, Ph.D., Chief Executive Officer, Arzeda. “These tools will accelerate our design-build-test cycle, which will enable us to get products to market faster,” he continued.
Michael Fero, Ph.D., Chief Executive Officer, TeselaGen, said, “I believe that the combination of Arzeda’s advanced computational design infrastructure with the TeselaGen platform will yield one of the most advanced information technology systems for the forward engineering of microbial systems in the world.”
He continued, “TeselaGen is building a platform that automates and optimizes protocol generation and information flow for biomanufacturing. Our hypothesis is that biotechnology is essentially an information technology. Improving the flow, handling and interpretation of information is a tremendous accelerant for biotech product development.”
“TeselaGen has created a unique solution for DNA assembly design,” said George McArthur, Ph.D., Research Scientist at Arzeda. “As an Alpha Access Program member, we have already significantly improved the efficiency of our genetic design-build workflow using TeselaGen’s genetic engineering CAD software. With this collaboration, we are looking forward to scaling our workflow even further.”
Arzeda, The Protein Design Company™, is harnessing the power of computational protein design and synthetic biology to create products that can compete on performance, cost and sustainability. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of proteins and specialty chemicals for polymers, advanced materials and health and nutrition products. Arzeda’s proprietary platform and validation process rapidly create “cell factories” that can be used at an industrial scale to solve problems and create opportunities that otherwise would be impossible. More information is available at www.arzeda.com.
TeselaGen has built a secure scalable enterprise quality software platform for synthetic biology, accelerating the development of medicines, improved crops, and sustainably sourced chemicals and materials. TeselaGen is privately held and is based in the software hub of San Francisco, CA. The company has received early recognition in the form of four US National Science Foundation funding awards, a US Department of Energy funding award and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution® technology for accelerate rapid prototyping of recombinant molecules. Follow TeselaGen on Twitter, and learn more at www.teselagen.com.